The latest purchase price of osimertinib (Tagressa) in 2024

Osimertinib is an oral targeted therapy drug that is widely used to treat non-small cell lung cancer (NSCLC). As a third-generation epidermal growth factor receptor (EGFR) inhibitor, osimertinib is unique in its high selectivity for EGFR mutations, especially its sensitivity to the EGFR T790M mutation, a common drug-resistant mutation.

Osimertinib has now entered the Chinese market and has also been included in the medical insurance system. Therefore, patients can purchase it in hospital pharmacies, and the price is approximately between NT$4,000 and NT$5,000. However, for specific costs and medical insurance reimbursement details, you need to consult the local hospital pharmacy for detailed consultation.

In addition, if you consider more economical options, foreign generics of osimertinib are cost-effective options, especially the versions produced in Laos and Bangladesh. Their prices are only about a few hundred yuan, which has a significant price advantage compared with domestic ones. It is worth mentioning that the ingredients of these generic drugs are highly consistent with those of domestic original drugs.

Osimertinib is mainly used to treat EGFR mutation-positive advanced NSCLC patients, especially those with EGFR T790M resistance mutations. This drug can block the growth and spread of cancer cells by inhibiting the activation of EGFR, thereby prolonging the patient's survival and improving the quality of life.

Compared with other first- and second-generation EGFR inhibitors, osimertinib has higher selectivity and stronger anti-tumor activity while having relatively few side effects. Common side effects include rash, diarrhea, fatigue, etc. Generally speaking, osimertinib is better tolerated than traditional chemotherapy.

In summary, osimertinib, as a targeted therapy, has shown significant efficacy and safety in patients with advancedNSCLC. Its high selectivity and good tolerability make it an important breakthrough in the treatment of lung cancer and provide patients with more treatment options. With in-depth research on its mechanism of action and clinical application, osimertinib is expected to continue to play an important role in the future and bring more hope to lung cancer patients.